Extensive evidence points to oxidative stress as a key event in the pathogenesis and exacerbation of Alzheimer's Disease (AD).[1] Transition metals, such as Zn, Fe, and Cu, are present in elevated concentrations in AD brain deposits, composed primarily of 40-or 42-mer amyloid beta (Aβ) peptides. The redox-active copper(II) ion binds to the unstructured, hydrophilic N terminus of Aβ; [1g,2] and the ability of copper to promote the formation of reactive oxygen species (ROS) and cause neuronal death by interaction with Aβ has been demonstrated in vitro. [1a,c,3,4] ROS formation is proposed to occur by interaction of reduced Cu I -Aβ with O 2 or H 2 O 2 . However, few direct studies of Cu I binding or reactivity with Aβ peptides or fragments have been reported. [5,6] We have studied the interactions of the hydrophilic N-terminal region of the Aβ peptide with Cu I . An understanding of the full redox competency of Cu-Aβ, leading to ROS formation and oxidative stress (that is, to cause events associated with the onset of AD), is incomplete without elucidation of the structure/function relationships of the reduced (active) copper(I)-peptide complexes. We report herein studies on the interaction of Cu I ions with small portions of the Aβ peptide incorporating specific metal-binding (His6, His13, His14) or potentially redoxactive (Tyr10) residues (Figure 1). Of considerable interest are the contiguous His13 and His14 residues. We have previously reported studies on Cu I complexes of modified (by end-capping and/or regiospecific N ε -or N δ -alkylation) His-His dipeptides which, significantly, adopt a two-coordinate, near-linear N His -Cu I -N His environment. [6] In this report, we demonstrate that Cu I complexes of longer Aβ peptide fragments adopt the same apparent two-coordinate structure in the solid state and aqueous solution. Preliminary reactivity investigations, described here, indicate that the His13-Cu I -His14 moiety is the active part of the structure, responsible for copper-Aβ reactivity.A range of peptides ( Figure 1) were synthesized and purified by reverse-phase (RP) HPLC to a single peak. Their identity and purity were confirmed by ESI mass spectrometry. The peptides